Pacer Advisors, Inc. Supernus Pharmaceuticals, Inc. Transaction History

Pacer Advisors, Inc.

$34.2 Billion
Q2 2025

A detailed history of Pacer Advisors, Inc. transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Pacer Advisors, Inc. holds 288,231 shares of SUPN stock, worth $11.9 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

288,231

Previous 403,628 28.59%

Holding current value

$11.9 Million

Previous $13.2 Million 31.27%

% of portfolio

0.03%

Previous 0.04%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 12, 2025	SELL	$30.29 - $33.43 $3.5 Million - $3.86 Million	-115,397 Reduced 28.59%	288,231 $9.09 Million
Q1 2025 May 06, 2025	SELL	$31.17 - $40.0 $37.2 Million - $47.8 Million	-1,193,828 Reduced 74.73%	403,628 $13.2 Million
Q4 2024 Jan 22, 2025	SELL	$31.89 - $37.83 $4.96 Million - $5.88 Million	-155,426 Reduced 8.87%	1,597,456 $57.8 Million
Q3 2024 Nov 12, 2024	BUY	$25.77 - $35.16 $10.4 Million - $14.2 Million	403,028 Added 29.86%	1,752,882 $54.7 Million
Q2 2024 Aug 13, 2024	BUY	$25.99 - $33.85 $35 Million - $45.6 Million	1,348,508 Added 100186.33%	1,349,854 $36.1 Million
Q1 2024 May 10, 2024	BUY	$27.11 - $35.17 $19,410 - $25,181	716 Added 113.65%	1,346 $45,000
Q4 2023 Jan 16, 2024	BUY	$22.72 - $29.68 $7,429 - $9,705	327 Added 107.92%	630 $18,000
Q3 2023 Nov 13, 2023	SELL	$27.57 - $32.91 $12.4 Million - $14.8 Million	-448,692 Reduced 99.93%	303 $8,000
Q2 2023 Jul 12, 2023	BUY	$29.91 - $38.73 $13.4 Million - $17.4 Million	448,995 New	448,995 $13.5 Million
Q4 2022 Feb 06, 2023	BUY	$31.09 - $37.88 $8.62 Million - $10.5 Million	277,169 New	277,169 $9.89 Million
Q4 2021 Feb 03, 2022	SELL	$26.37 - $34.22 $2.4 Million - $3.11 Million	-90,866 Closed	0 $0
Q3 2021 Oct 15, 2021	SELL	$23.54 - $31.39 $121,654 - $162,223	-5,168 Reduced 5.38%	90,866 $2.42 Million
Q2 2021 Jul 21, 2021	BUY	$26.72 - $33.19 $1.08 Million - $1.34 Million	40,518 Added 72.98%	96,034 $2.96 Million
Q1 2021 Apr 05, 2021	BUY	$24.15 - $31.45 $893,936 - $1.16 Million	37,016 Added 200.09%	55,516 $1.45 Million
Q4 2020 Jan 20, 2021	BUY	$17.7 - $25.81 $54,462 - $79,417	3,077 Added 19.95%	18,500 $465,000
Q3 2020 Oct 19, 2020	BUY	$20.2 - $25.05 $149,601 - $185,520	7,406 Added 92.38%	15,423 $321,000
Q2 2020 Jul 29, 2020	SELL	$17.09 - $24.89 $35,598 - $51,845	-2,083 Reduced 20.62%	8,017 $190,000
Q1 2020 Apr 23, 2020	SELL	$14.45 - $24.69 $155,351 - $265,442	-10,751 Reduced 51.56%	10,100 $201,000
Q4 2019 Feb 10, 2020	SELL	$19.93 - $29.13 $48,868 - $71,426	-2,452 Reduced 10.52%	20,851 $495,000
Q3 2019 Oct 10, 2019	BUY	$25.47 - $33.37 $178,417 - $233,756	7,005 Added 42.98%	23,303 $640,000
Q2 2019 Aug 12, 2019	BUY	$29.96 - $38.87 $67,110 - $87,068	2,240 Added 15.93%	16,298 $539,000
Q1 2019 Apr 10, 2019	BUY	$32.77 - $41.99 $68,751 - $88,095	2,098 Added 17.54%	14,058 $493,000
Q4 2018 Feb 13, 2019	BUY	$30.84 - $49.51 $368,846 - $592,139	11,960 New	11,960 $397,000

Others Institutions Holding SUPN

# of Institutions

312

Shares Held

61.6M

Call Options Held

18.4K

Put Options Held

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $2.21B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pacer Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Pacer Advisors, Inc. with notifications on news.

Account

Pacer Advisors, Inc. Supernus Pharmaceuticals, Inc. Transaction History